Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Prostate Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
31 drugs · 100 active trials
7 drugs · 60 active trials
24 drugs · 406 active trials
Outside the funnel: Withdrawn 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 11 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Aldesleukin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 1995-01 |
| Alisertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2010 |
| Axitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Oct 28, 2011 |
| Daratumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Mar 1, 2017 |
| Dovitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | May 19, 2014 |
| Epirubicin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2002-07 |
| Eribulin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-11 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2001-12 |
| Exemestane | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2001-08 |
| Ganetespib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2011-01 |
| Imiquimod | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2004-04 |
| Neratinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Apr 1, 2020 |
| Perifosine | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2003-03 |
| Ribociclib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Nov 20, 2015 |
| Ridaforolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2005-05 |
| Romidepsin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | May 7, 2003 |
| Selinexor | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2014-05 |
| Trabectedin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2002-06 |
| Tretinoin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Aug 20, 2018 |
| Vatalanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2005-02 |
| 2-Deoxy-D-glucose | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2006-11 |
| Adebrelimab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 30, 2024 |
| Aminoglutethimide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2000-05 |
| Apitolisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 11, 2012 |
| Arsenic Trioxide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 1999-09 |
| Carfilzomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2014-04 |
| Carmustine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 1998-09 |
| Cetuximab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-06 |
| Cinacalcet | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-09 |
| Cytarabine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-04 |
| Decitabine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 15, 2021 |
| Ibrutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2016-07 |
| Ibuprofen | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | May 1, 2018 |
| Lestaurtinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-03 |
| Linsitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-02 |
| Melphalan | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 1998-09 |
| Olaratumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-10 |
| Onalespib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-09 |
| Pexidartinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | May 25, 2012 |
| Pomalidomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2003-09 |
| Prexasertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 20, 2015 |
| Radiation Therapy | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-03 |
| Ramucirumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-08 |
| Retaspimycin Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-11 |
| Rilotumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-11 |
| Seribantumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 29, 2020 |
| Tandutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2006-10 |
| Taxol | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2000-06 |
| Tipifarnib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2000-04 |
| Topotecan | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2003-11 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.